JP2014510704A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510704A5
JP2014510704A5 JP2013546310A JP2013546310A JP2014510704A5 JP 2014510704 A5 JP2014510704 A5 JP 2014510704A5 JP 2013546310 A JP2013546310 A JP 2013546310A JP 2013546310 A JP2013546310 A JP 2013546310A JP 2014510704 A5 JP2014510704 A5 JP 2014510704A5
Authority
JP
Japan
Prior art keywords
pharmaceutical tablet
tablet
pharmaceutical
drug
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510704A (ja
JP6126014B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/066021 external-priority patent/WO2012088033A2/en
Publication of JP2014510704A publication Critical patent/JP2014510704A/ja
Publication of JP2014510704A5 publication Critical patent/JP2014510704A5/ja
Application granted granted Critical
Publication of JP6126014B2 publication Critical patent/JP6126014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546310A 2010-12-20 2011-12-20 新規医薬組成物 Active JP6126014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
US61/424,967 2010-12-20
PCT/US2011/066021 WO2012088033A2 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017007796A Division JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Publications (3)

Publication Number Publication Date
JP2014510704A JP2014510704A (ja) 2014-05-01
JP2014510704A5 true JP2014510704A5 (enExample) 2015-02-05
JP6126014B2 JP6126014B2 (ja) 2017-05-10

Family

ID=46314827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013546310A Active JP6126014B2 (ja) 2010-12-20 2011-12-20 新規医薬組成物
JP2017007796A Withdrawn JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017007796A Withdrawn JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Country Status (38)

Country Link
US (5) US8580304B2 (enExample)
EP (4) EP4159204B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159204T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2820536T3 (enExample)
FI (2) FI4159204T3 (enExample)
HR (3) HRP20240564T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159204T3 (enExample)
PT (3) PT4159204T (enExample)
RS (2) RS65497B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI2654736T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
PE20151024A1 (es) * 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
CN109789141B (zh) * 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
CA3041561A1 (en) * 2016-11-25 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (ko) 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
BR112012006693A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
BR112012006485A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
WO2011038380A2 (en) * 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
CN104382906A (zh) 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
JP5903433B2 (ja) * 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Similar Documents

Publication Publication Date Title
JP6770946B2 (ja) 2−フルオロ−n−メチル−4−[7−(キノリン−6−イルメチル)イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの錠剤
HRP20201409T1 (hr) Novi farmaceutski pripravak
CN103599083B (zh) 左旋奥拉西坦缓释片及其制备方法
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP2015157851A5 (enExample)
JP2016528302A5 (enExample)
CN115554257A (zh) 瑞博西尼片剂
TWI700100B (zh) 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法
KR20150079454A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
JP2015530355A (ja) 低用量エンテカビルの経口投与製剤の製造方法
AU2007314282A1 (en) Elvucitabine pharmaceutical compositions
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
CN106176640B (zh) 一种含枸橼酸托法替布的药物组合物及其制备方法
CN104840960A (zh) 抗糖尿病的药物组合物及其制备方法
CN105263479A (zh) 调整释放制剂
JP6243351B2 (ja) パーキンソン病の固定投与量薬剤組合せ治療
JP2018150384A (ja) 口腔内崩壊錠及びその製造方法
CN101711765B (zh) 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片
TWI704918B (zh) 含有細胞周期蛋白抑制劑的藥物製劑及其製備方法
CN106309388A (zh) 一种用于心衰治疗的药物组合物及其制备方法
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
CN102342940B (zh) 制备抗结核病的组合的改良方法及由其制得的医药组合物
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
CN106924388B8 (zh) 一种治疗失眠的药物组合物及其制备方法、制剂与应用
CA2925960A1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide